^Youn DH, Kim JM, Hong YK, Park SI, Lee JM, Kim YH, et al. (August 2021). "Assessment of the abuse potential of methamnetamine in rodents: a behavioral pharmacology study".Psychopharmacology.238 (8):2155–2165.doi:10.1007/s00213-021-05840-9.PMID33811503.S2CID232773019.
^Hong YK, Kim YH, Lee JM, Yoo HH, Choi SO, Kang MS (July 2021). "Characterization of in vitro phase I metabolites of methamnetamine in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry".International Journal of Legal Medicine.135 (4):1471–1476.doi:10.1007/s00414-021-02594-z.PMID33928430.S2CID233451101.
^Stalberga, D., Kronstrand, R., Schranz, B., van Zijl, N., Karlman, S., Aref, S., ... & Gréen, H. (2025). Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5HT2A receptor.https://doi.org/10.22541/au.176253891.19158813/v1
^abGlennon RA, Dukat M (2017). "Structure-Activity Relationships of Synthetic Cathinones".Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. Springer. pp. 19–47.doi:10.1007/7854_2016_41.ISBN978-3-319-52442-9.PMC5818155.PMID27830576.
^abPartilla JS, Dersch CM, Baumann MH, Carroll FI, Rothman RB (1999). "Profiling CNS Stimulants with a High-Throughput Assay for Biogenic Amine Transporter Substractes".Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc(PDF). NIDA Res Monogr. Vol. 180. pp. 1–476 (252).PMID11680410. Archived fromthe original(PDF) on August 5, 2023.RESULTS. Methamphetamine and amphetamine potently released NE (IC50s = 14.3 and 7.0 nM) and DA (IC50s = 40.4 nM and 24.8 nM), and were much less potent releasers of 5-HT (IC50s = 740 nM and 1765 nM). Phentermine released all three biogenic amines with an order of potency NE (IC50 = 28.8 nM)> DA (IC50 = 262 nM)> 5-HT (IC50 = 2575 nM). Aminorex released NE (IC50 = 26.4 nM), DA (IC50 = 44.8 nM) and 5-HT (IC50 = 193 nM). Chlorphentermine was a very potent 5-HT releaser (IC50 = 18.2 nM), a weaker DA releaser (IC50 = 935 nM) and inactive in the NE release assay. Chlorphentermine was a moderate potency inhibitor of [3H]NE uptake (Ki = 451 nM). Diethylpropion, which is self-administered, was a weak DA uptake inhibitor (Ki = 15 µM) and NE uptake inhibitor (Ki = 18.1 µM) and essentially inactive in the other assays. Phendimetrazine, which is self-administered, was a weak DA uptake inhibitor (IC50 = 19 µM), a weak NE uptake inhibitor (8.3 µM) and essentially inactive in the other assays.
^Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, Baumann MH (June 2005). "Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration".The Journal of Pharmacology and Experimental Therapeutics.313 (3):1361–1369.doi:10.1124/jpet.104.082503.PMID15761112.S2CID19802702.
^Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA (October 2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates".The Journal of Pharmacology and Experimental Therapeutics.307 (1):138–145.doi:10.1124/jpet.103.053975.PMID12954796.S2CID19015584.
^Nicole, Lauren (2022)."In vivo Structure-Activity Relationships of Substituted Amphetamines and Substituted Cathinones".ProQuest. Retrieved5 December 2024.FIGURE 2-6: Release: Effects of the specified test drug on monoamine release by DAT (red circles), NET (blue squares), and SERT (black traingles) in rat brain tissue. [...] EC50 values determined for the drug indicated within the panel. [...]
^Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, Baumann MH (June 2002). "Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain".European Journal of Pharmacology.447 (1):51–57.doi:10.1016/s0014-2999(02)01830-7.PMID12106802.
^"指定薬物名称・構造式一覧（平成27年9月16日現在）" [List of designated drug names and structural formulas (as of September 16, 2015)](PDF).厚生労働省 [Ministry of Health, Labour and Welfare] (in Japanese). 16 September 2015. Retrieved8 October 2015.
